Abstract
Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.
Keywords: Reduced-intensity stem cell transplantation, graft-versus-host disease, graft-versus-leukemia effect, mixed chimerism, regimen-related toxicity
Current Stem Cell Research & Therapy
Title: Reduced-Intensity Stem Cell Transplantation for Hematological Malignancies: Current Status and the Future
Volume: 2 Issue: 2
Author(s): Koji Kato, Yasser Khaled and Shin Mineishi
Affiliation:
Keywords: Reduced-intensity stem cell transplantation, graft-versus-host disease, graft-versus-leukemia effect, mixed chimerism, regimen-related toxicity
Abstract: Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.
Export Options
About this article
Cite this article as:
Kato Koji, Khaled Yasser and Mineishi Shin, Reduced-Intensity Stem Cell Transplantation for Hematological Malignancies: Current Status and the Future, Current Stem Cell Research & Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157488807780599248
DOI https://dx.doi.org/10.2174/157488807780599248 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Trends in the Treatment of Hepatocellular Carcinoma
Current Drug Therapy Future Approaches for Treating Hematologic Disease
Current Pharmaceutical Biotechnology KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
Current Molecular Medicine Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772)
Current Cancer Drug Targets Etanercept for the Treatment of Dermatological Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control
Current Cancer Therapy Reviews Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies
Current Medicinal Chemistry MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Cratylia mollis Lectin: A Versatile Tool for Biomedical Studies
Current Bioactive Compounds <i>In Vivo</i> Antitumor, Pharmacological and Toxicological Study of Pyrimido[ 4′,5′:4,5] thieno(2,3-b)quinoline with 9-hydroxy-4-(3-diethylaminopropylamino) and 8-methoxy-4-(3-diethylaminopropylamino) Substitutions
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders